1. Home
  2. PENN vs PHVS Comparison

PENN vs PHVS Comparison

Compare PENN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PENN Entertainment Inc.

PENN

PENN Entertainment Inc.

HOLD

Current Price

$11.85

Market Cap

1.7B

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.45

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PENN
PHVS
Founded
1972
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
PENN
PHVS
Price
$11.85
$26.45
Analyst Decision
Buy
Buy
Analyst Count
16
9
Target Price
$20.50
$39.44
AVG Volume (30 Days)
4.4M
138.4K
Earning Date
02-26-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,823,800,000.00
N/A
Revenue This Year
$7.19
N/A
Revenue Next Year
$3.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.24
N/A
52 Week Low
$11.66
$11.51
52 Week High
$23.08
$29.80

Technical Indicators

Market Signals
Indicator
PENN
PHVS
Relative Strength Index (RSI) 35.66 49.00
Support Level $12.19 $25.69
Resistance Level $14.00 $28.79
Average True Range (ATR) 0.70 1.47
MACD -0.06 -0.11
Stochastic Oscillator 7.85 39.61

Price Performance

Historical Comparison
PENN
PHVS

About PENN PENN Entertainment Inc.

Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: